Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound. The company's marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc.; The University of Texas MD Anderson Cancer Center; Provention Bio, Inc.; and Molecular Partners AG. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone805-447-1000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$22.85 billion
Profitability
Miscellaneous
Employees20,800
OptionableOptionable
Amgen (NASDAQ:AMGN) Frequently Asked Questions
What is Amgen's stock symbol?
Amgen trades on the NASDAQ under the ticker symbol "AMGN."
How often does Amgen pay dividends? What is the dividend yield for Amgen?
Amgen announced a quarterly dividend on Friday, December 7th. Investors of record on Friday, February 15th will be given a dividend of $1.45 per share on Friday, March 8th. This represents a $5.80 annualized dividend and a yield of 2.84%. The ex-dividend date is Thursday, February 14th. This is a positive change from Amgen's previous quarterly dividend of $1.32. View Amgen's Dividend History.
How will Amgen's stock buyback program work?
Amgen announced that its board has approved a stock repurchase program on Friday, February 2nd 2018, which permits the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to repurchase shares of its stock through open market purchases. Shares buyback programs are typically a sign that the company's leadership believes its stock is undervalued.
How were Amgen's earnings last quarter?
Amgen, Inc. (NASDAQ:AMGN) issued its quarterly earnings data on Tuesday, October, 30th. The medical research company reported $3.69 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $3.45 by $0.24. The medical research company had revenue of $5.90 billion for the quarter, compared to analyst estimates of $5.78 billion. Amgen had a net margin of 9.44% and a return on equity of 54.14%. Amgen's revenue was up 2.3% on a year-over-year basis. During the same quarter in the prior year, the business posted $3.27 EPS. View Amgen's Earnings History.
When is Amgen's next earnings date?
How can I listen to Amgen's earnings call?
Amgen will be holding an earnings conference call on Tuesday, January 29th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 8558554105.
What guidance has Amgen issued on next quarter's earnings?
Amgen updated its FY18 earnings guidance on Tuesday, October, 30th. The company provided EPS guidance of $14.00-14.25 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $14.03. The company issued revenue guidance of $23.2-23.5 billion, compared to the consensus revenue estimate of $23.20 billion.Amgen also updated its FY 2018 guidance to $14.00-14.25 EPS.
What price target have analysts set for AMGN?
20 brokerages have issued 1 year target prices for Amgen's stock. Their predictions range from $179.00 to $232.00. On average, they expect Amgen's share price to reach $204.8005 in the next year. This suggests a possible upside of 0.5% from the stock's current price. View Analyst Price Targets for Amgen.
What is the consensus analysts' recommendation for Amgen?
20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 12 hold ratings and 8 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Amgen.
What are Wall Street analysts saying about Amgen stock?
Here are some recent quotes from research analysts about Amgen stock:
- 1. According to Zacks Investment Research, "Amgen’s newer drugs – Prolia, Xgeva, Blincyto, Kyprolis – are performing well. Amgen is also progressing with its pipeline and the approval of migraine candidate, Aimovig was a huge boost. Its strong biosimilars pipeline could be an important long-term growth driver. Amgen’s restructuring plan is making more cost efficient. Lower taxes and share buybacks should provide some bottom-line support. Amgen’s shares have outperformed the industry in the past year. However, Amgen faces challenges related to its more mature products such as launch of competing biosimilar versions of Neulasta and Epogen, further sales erosion of Neupogen and Aranesp and increasing competitive pressures on Enbrel. Meanwhile, uptake of key new drug, Repatha has been slow due to payer restrictions. Nonetheless, estimates have gone up ahead of the Q4 earnings release. Amgen has a positive record of earnings surprises in recent quarters." (1/14/2019)
- 2. Cantor Fitzgerald analysts commented, "We visited Amgen’s headquarters in conjunction with our post ASH bus tour and met the company’s CFO, R&D head, and IR team. We highlight key takeaways in this note. Management continues to sound very bullish about the Aimovig launch even as competitors launch. We could expect a decision on the Sandoz case around the mediation in Jan. We would expect 2019 guidance range to be as wide or a bit wider than 2018 due to biosimilars. From speaking to management, we think the biggest moving piece is Neulasta experiencing now two biosimilar competitors. When looking at analogs, the company notes drug lost about 50% share, but Amgen has the OnPro device, which may allow it to slow the rate of branded loss. Sensipar ($1.7B ’18 Bloomberg consensus) is a moving piece since generics have not launched at risk." (12/4/2018)
- 3. Mizuho analysts commented, ". After speaking with two physicians who treat between 50-100 patients per month for cellulite to discuss the market opportunity for ENDP’s CCH, we are increasingly more positive on the market opportunity for this product, if approved. We are still maintaining our Neutral rating because we think the risk reward for ENDP’s existing business and new opportunities is already accurately reflected in its stock price. Better-than-expected Phase 3 data for CCH, a pick up in ENDP’s generics business and/or lower-than-expected calls on ENDP’s cash (debt, testosterone) would make us more positive on the stock. Please contact your Cantor Fitzgerald representative for a replay of the call." (10/26/2018)
Has Amgen been receiving favorable news coverage?
News headlines about AMGN stock have been trending very positive on Tuesday, InfoTrie reports. The research firm identifies positive and negative media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Amgen earned a media sentiment score of 3.2 on InfoTrie's scale. They also assigned headlines about the medical research company a news buzz of 4.0 out of 10, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are some of Amgen's key competitors?
Some companies that are related to Amgen include Gilead Sciences (GILD), Biogen (BIIB), NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), BIO-TECHNE (TECH), Ablynx (ABLYF), Allogene Therapeutics (ALLO), argenx (ARGX), China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO) and Denali Therapeutics (DNLI).
Who are Amgen's key executives?
Amgen's management team includes the folowing people:
- Mr. Robert A. Bradway, Chairman & CEO (Age 55)
- Mr. David W. Meline, Exec. VP & CFO (Age 61)
- Mr. Jonathan P. Graham, Sr. VP, Gen. Counsel & Sec. (Age 57)
- Dr. Sean E. Harper, Non-Exec. Officer (Age 55)
- Mr. Esteban Santos, Exec. VP of Operations (Age 50)
Who are Amgen's major shareholders?
Amgen's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Gateway Investment Advisers LLC (0.06%), Nisa Investment Advisors LLC (0.05%), Retirement Systems of Alabama (0.05%), Douglass Winthrop Advisors LLC (0.04%), Ferguson Wellman Capital Management Inc. (0.03%) and Personal Capital Advisors Corp (0.03%). Company insiders that own Amgen stock include Carbonnel Francois De, Cynthia M Patton, Sean E Harper and Tyler Jacks. View Institutional Ownership Trends for Amgen.
Which institutional investors are selling Amgen stock?
AMGN stock was sold by a variety of institutional investors in the last quarter, including Gulf International Bank UK Ltd, Retirement Systems of Alabama, Nisa Investment Advisors LLC, Bowling Portfolio Management LLC, Sit Investment Associates Inc., Granite Investment Advisors LLC, Legacy Advisors LLC and DNB Asset Management AS. Company insiders that have sold Amgen company stock in the last year include Cynthia M Patton, Sean E Harper and Tyler Jacks. View Insider Buying and Selling for Amgen.
Which institutional investors are buying Amgen stock?
AMGN stock was bought by a variety of institutional investors in the last quarter, including CHURCHILL MANAGEMENT Corp, Grassi Investment Management, R.H. Dinel Investment Counsel Inc., Pensionfund DSM Netherlands, Douglass Winthrop Advisors LLC, Diversified Trust Co, Benson Investment Management Company Inc. and Pensionfund Sabic. View Insider Buying and Selling for Amgen.
How do I buy shares of Amgen?
Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Amgen's stock price today?
One share of AMGN stock can currently be purchased for approximately $203.88.
How big of a company is Amgen?
Amgen has a market capitalization of $129.92 billion and generates $22.85 billion in revenue each year. The medical research company earns $1.98 billion in net income (profit) each year or $12.58 on an earnings per share basis. Amgen employs 20,800 workers across the globe.
What is Amgen's official website?
How can I contact Amgen?
Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]
MarketBeat Community Rating for Amgen (NASDAQ AMGN)
MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe AMGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
